Results 121 to 130 of about 5,710 (181)

Evolocumab Alters Transcriptomic Signatures and Identifies Inflammatory Biomarkers in Brain-Heart Syndrome with Coronary Heart Disease History. [PDF]

Int J Gen Med
Dong H, Gong X, Zhao Z, Joyama Y, Ji X, Qu P.   +5 more
europepmc   +1 more source

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. [PDF]

J Lipid Res
Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chiruvolu P, Jackson S, Di M, Peach M, Somaratne R, Wasserman SM, Scott R, Stein EA.   +16 more
europepmc   +1 more source

Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients. [PDF]

J Atheroscler Thromb
Oyama K, Yoshida M, Kiyosue A, Osada N, Sheng F, Harada N, Miyawaki K, Shimauchi J, Fu Y, Yamashita S.   +9 more
europepmc   +1 more source

Impact of early initiation of PCSK9I monoclonal antibodies after acute coronary syndrome. [PDF]

Indian Heart J
Goel PK, Kapoor A, Jain KJ, Thachathodiyl R, Reddy V, Guleria V, Bhalla N, Sasidharan S.   +7 more
europepmc   +1 more source

Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab. [PDF]

Rev Cardiovasc Med
Sabouret P, Giamundo DM, Mamas M.
europepmc   +1 more source

PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia. [PDF]

J Cell Mol Med
Woźniak-Szczepocka A, Pawlos A, Gorzelak-Pabiś P, Broncel M, Bukowska B, Woźniak E.   +5 more
europepmc   +1 more source

PCSK9 inhibition after heart transplantation: how low does low-density lipoprotein cholesterol need to go for cardiac allograft vasculopathy prevention? [PDF]

J Thorac Dis
Weis M.
europepmc   +1 more source

PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study. [PDF]

Eur Heart J Suppl
Gatto L, Di Bitonto MP, Scalia L, Biccirè FG, Prati F.   +4 more
europepmc   +1 more source

Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease. [PDF]

J Saudi Heart Assoc
AlHabeeb W, Alamri H, Elbadawi H, AlRuthia YS, Alharbi W, Alshammeri O, Tash A, Almoziny S, Kholaif N, Halawani H, AlMahdi F, Yar W, Alhabib KF.   +12 more
europepmc   +1 more source

Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence. [PDF]

Front Endocrinol (Lausanne)
Yang XH, Liu Y, Fu CS, Jin HM, Ye ZB.
europepmc   +1 more source